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Abstract 
Background: Malaria in pregnancy (MiP) is a major cause of fetal growth restriction and low birth weight in endemic 
areas of sub-Saharan Africa. Understanding of the impact of MiP on infant growth and infant risk of malaria or morbid-
ity is poorly characterized. The objective of this study was to describe the impact of MIP on subsequent infant growth, 
malaria and morbidity.
Methods: Between 2006 and 2009, 82 % (832/1018) of pregnant women with live-born singletons and ultrasound 
determined gestational age were enrolled in a prospective cohort with active weekly screening and treatment 
for malaria. Infants were followed monthly for growth and morbidity and received active monthly screening and 
treatment for malaria during their first year of life. Multivariate analyses were performed to analyse the association 
between malaria exposure during pregnancy and infants’ growth, malaria infections, diarrhoea episodes and acute 
respiratory infections.
Results: Median time of infant follow-up was 12 months and infants born to a mother who had MiP were at 
increased risk of impaired height and weight gain (−2.71 cm, 95 % CI −4.17 to −1.25 and −0.42 kg, 95 % CI −0.76 to 
−0.08 at 12 months for >1 MiP compared to no MiP) and of malaria infection (relative risk 10.42, 95 % CI 2.64–41.10 for 
infants born to mothers with placental malaria). The risks of infant growth restriction and infant malaria infection were 
maximal when maternal malaria occurred in the 12 weeks prior to delivery. Recurrent MiP was also associated with 
acute respiratory infection (RR 1.96, 95 % CI 1.25–3.06) and diarrhoea during infancy (RR 1.93, 95 % CI 1.02–3.66).
Conclusion: This study shows that despite frequent active screening and prompt treatment of MiP, impaired growth 
and an increased risk of malaria and non-malaria infections can be observed in the infants. Effective preventive meas-
ures in pregnancy remain a research priority.
This study was registered with ClinicalTrials.gov, number NCT00495508.
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Background
Malaria in pregnancy (MiP) remains a leading cause 
of miscarriage, preterm delivery, intrauterine growth 
restriction (IUGR) and low birth weight (LBW) in 
malaria-endemic areas of sub-Saharan Africa, Asia and 
South America [1–5]. As a result, MiP increases the risk 
of perinatal mortality as well as reducing the capacity 
of the child to develop to his/her full potential in these 
settings. The impact of MiP on infant growth and infant 
risk of malaria or morbidity, in contrast to adverse birth 
outcomes, is infrequently reported. Only two studies 
have investigated the relation between MiP and infant 
growth and found that placental or peripheral malaria at 
delivery was independently associated with lower weight 
at 12  months [6, 7]. Other studies have investigated 
the effect of MiP on the risk of malaria in infants but 
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mixed results have been reported [8–15]. Some studies 
observed an increased risk of malaria in infants born to 
multigravida women with placental infection [9, 11], but 
this was not confirmed by others [10, 12]. Apart from the 
risk of malaria, there is a paucity of data on other mor-
bidities commonly found in infants such as diarrhoea and 
pneumonia and on their association with MiP.
MiP may increase infant morbidity through different 
mechanisms. First, MiP is responsible for IUGR and pre-
term birth that are, in turn, associated with infant mor-
tality and morbidity [16–19]. Also, there is increasing 
evidence showing maternal immune response and fetal 
immune system are in a highly dynamic state [20]. It has 
been suggested that the inflammatory response follow-
ing placental malaria infection may lead to some immu-
nological tolerance in the offspring [21, 22]. Moreover, 
the consequences of in utero infection may vary with 
maternal gravidity [11] and with the gestational age of 
exposure [23]. The accurate determination of both ges-
tational age (GA) and weight at birth is, therefore, an 
important factor that should be included in the analysis 
of the effect of MiP on the risk of malaria infection in 
infant [24].
The objective of this work was to analyse the effect of 
MiP on infant growth and morbidity, (including malaria) 
with respect to MiP timing using data from a prospec-
tively and previously published cohort of pregnant 
women and their infants [24]. This work differs to most 
previously published work from sub-Saharan Africa 
because GA was documented by ultrasound and the 
detection of malaria during pregnancy was active and 
frequent with regular screening at each visit with prompt 
treatment for mothers and infants.
Methods
Population and setting
This mother–baby cohort study was conducted in Mba-
rara district, southwestern Uganda. This predominantly 
rural area lies at an altitude of about 1500  m above sea 
level and has a tropical climate with a bimodal rain-
fall pattern averaging 1200  mm per annum in Septem-
ber–January and March–May. Malaria transmission was 
considered as mesoendemic although significant hetero-
geneity has been observed recently [25, 26].
Study design
The study design was a prospective cohort of 1218 preg-
nant women of estimated GA ≥13  weeks with a nested 
clinical trial conducted between October 2006 and May 
2009, in which 304 pregnant women were enrolled [27]. 
All women with a positive blood smear were invited 
to participate in a study comparing the efficacy and 
tolerance of artemether–lumefantrine (AL) with oral 
quinine for the treatment of uncomplicated falciparum 
malaria of whom 304 met the criteria and consented 
[27]. Newborns of mothers enrolled in the cohort were 
included in a birth cohort and actively followed until 
12  months. Only live-born singletons with accurate GA 
estimation were included in this analysis.
Clinical and monitoring procedures
At enrolment, a comprehensive assessment of the 
mothers was performed that included the collection of 
information on their demographic, socioeconomic, med-
ical and obstetric characteristics, a clinical and obstet-
ric examination, an ultrasound evaluation, blood smear 
and haemoglobin measurements. An estimation of GA 
by ultrasound for foetal biometry using biparietal diam-
eter and femur length was performed between 16 and 
22 weeks of pregnancy [28]. After the initial assessment, 
mothers were followed every week. Malaria infection was 
systematically screened using a Paracheck Pf® (Orchid, 
Goa, India) rapid diagnostic test (RDT) and confirmed 
with a blood smear test.
Women in the cohort received standard supervised IPT 
with two doses of sulfadoxine-pyrimethamine (SP) given 
at intervals of one month or more during the second and 
third trimesters as recommended by national guidelines. 
IPT was not given to the women who receive anti-malar-
ial treatment (quinine or AL). All treatments were pro-
vided free-of-charge.
At delivery, blood smears were obtained from the 
mother, the placenta, cord and from the newborn to 
verify the presence of malaria infection. Newborns were 
weighed to the nearest 10  g using a SECA mechanical 
type scale and received an initial standardized physical 
examination by a medical officer. Length was measured 
using a Stadiometer. After the initial evaluation, infants 
were seen every month or more frequently if required 
until 12  months. At each visit, anthropometric char-
acteristics were measured once, malaria infection was 
screened with a Paracheck® RDT and treated with AL, 
and a medical examination by a paediatrician was per-
formed. Morbidity definitions in infancy were based on 
national guidelines [29].
Laboratory procedures
Thick and thin blood smears were prepared and stained 
with Giemsa. Parasitaemia was calculated by counting 
parasites against 200 white blood cells. Placenta smears 
were taken by incising a fresh placenta on the maternal 
surface halfway between the cord and the periphery.
HIV testing and treatment was proposed for all women 
and performed according to the national guidelines.
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Definition
Small-for-GA (SGA) was defined as a birth weight less 
than the 10th percentile of sex-specific birth weight-for-
GA [30]. Peripheral malaria infection was defined as the 
occurrence of a positive peripheral blood smear or rapid 
diagnostic test. Placental malaria was defined as the 
detection of any parasite in a placental blood smear by 
microscopy.
Statistical analysis
Infant outcomes
The change in weight and height between birth and 
12 months (weight and height gain) were analysed using a 
linear model. Missing data at 12 months because of irreg-
ular visit schedules (n = 150/794) were imputed and con-
fidence intervals were adapted using Rubin’s formula [31, 
32]. The other outcomes considered in this analysis were 
the time to the first malaria infection in infancy (defined 
by a positive RDT), the time to first diarrhoea episode 
and the time to first acute respiratory infection. Their 
association with the explanatory variables was assessed 
with a Poisson model [33, 34].
Explanatory variables
Two categories of explanatory variables were considered 
in the analysis:
  • Malaria exposure during pregnancy The occurrence 
of any peripheral malaria infection, the number (0, 1 
or >1) of peripheral malaria infections and the occur-
rence of placental malaria infection were considered 
in the analysis. To investigate if infant outcomes were 
associated with malaria infections occurring at a spe-
cific time during pregnancy, four time periods were 
defined starting from delivery; first 4  weeks before 
delivery, 4–12  weeks before delivery, 12–20  weeks 
before delivery and >20  weeks before delivery. As 
women were followed up from their first antenatal 
visit, malaria infection may have occurred before 
inclusion in the study and exposure to malaria during 
pregnancy was incompletely observed resulting in 
left-censoring. This missing information should not 
be coded as the absence of malaria infection, which 
may result in misclassification of true exposure but 
accounted for using statistical method for left-cen-
soring [35]. In this analysis, multiple-imputation was 
used for measurement-error correction as detailed in 
“Appendix”.
  • Maternal characteristics and other potential con-
founders Education level, mother age, gravidity, resi-
dential area, season, maternal HIV infection status 
and use of a bed net were considered in the analysis 
as potential confounders and included in all multi-
variate models. GA was also included as a covariate 
to account for the effect of preterm birth on infant 
growth.
  • Potential effect modifier Maternal gravidity (primi-
gravidae vs multigravidae) was also assessed as 
potential effect modifiers of malaria exposure.
This study was powered to assess the primary outcome 
and not for this secondary analysis. All analyses were per-
formed using the open source statistical software R [36].
Ethical approval
The study was approved by the institutional review 
boards of Mbarara University of Science and Technology, 
Uganda National Council for Science and Technology, 
and France’s “Comité de protection des personnes—Ile-
de-France XI”. This study was registered with ClinicalTri-
als.gov, number NCT00495508.
Role of the funding source
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Study population characteristics
Of the 1218 women enrolled in the cohort, 60  % were 
enrolled before 20  weeks gestation, 1069 had delivery 
outcomes, and 1018 newborns were enrolled in the infant 
cohort. There were 832 (82 %) live-born singletons with 
a valid ultrasound assessment of GA included in this 
analysis (Fig. 1). The infants were followed for a median 
time of 12 months and 94 % had a follow-up ≥12 months. 
Mother and infant characteristics are summarized in 
Table  1 including the median (IQR) number of screens 
21 (17–24) and doses of IPTp SP (68  % ≥2doses) pro-
vided to mothers. Infants who were included in this 
study were born to mothers with a greater education 
level (p = 0.001) and enrolled at a lower gestational age 
in the cohort (p  <  0.001) when compared to those who 
were excluded. Peripheral malaria during pregnancy was 
observed in 198 (23 %) mothers and evidence of placental 
malaria was found in 15 (3 %) of the 490 placentas avail-
able. Mothers with placental malaria were included later 
in the study compared to those without placental infec-
tion (p = 0.002).
Infant growth
Of the 794 children with weight data, 141 (19  %) were 
SGA at birth. In adjusted analysis without including 
malaria variables, weight gain at 12  months was lower 
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in girls, infants born by vaginal delivery, infants born 
to mothers infected with HIV and in those born SGA, 
while height gain was greater in boys, preterm infants 
and in those born to mothers with higher education level 
(Table 2).
A complex relation between malaria infection during 
pregnancy and growth was observed (Fig.  2). Overall, 
infants born to mothers exposed to >1 episode of MiP 
had significantly impaired height and weight gains when 
compared to those born to mothers not infected dur-
ing pregnancy (respectively −2.71 cm, 95 % CI −4.17 to 
−1.25 and −0.42  kg, 95  % CI −0.76 to −0.08 in multi-
variate analyses). Infants born to mothers with placental 
malaria had significantly impaired weight gain (−0.65 kg, 
95 % CI −1.16 to −0.13). There was no significant inter-
action between MiP and maternal gravidity (p = 0.7 and 
0.1, respectively).
As displayed in Fig. 3 (upper panels), the risk of height 
and weight growth restriction was maximal for malaria 
infections occurring in the 12  weeks prior to deliv-
ery (respectively, −1.39, 95  % CI −2.76 to −0.03 and 
−0.28, 95 % CI −0.60 to 0.03, p = 0.07 for malaria infec-
tions occurring between 4 and 12  weeks before deliv-
ery) and declined the earlier in pregnancy the infection 
was detected and treated. A single infection promptly 
and effectively treated before 20 weeks without parasite 
reappearance had no significant modifying effect on 
infant weight growth (+0.03, 95  % CI −0.27 to 0.33, 
p = 0.9).
Fig. 1 Flow chart
Table 1 Characteristics of the study population
Mother characteristics
Median maternal age, year (IQR) 24 (21–27)
Primigravid, n (%) 311 (37)
Residence, n (%)
 Urban 446 (63)
 Rural 386 (37)
Education level, n (%)
 No education 85 (10)
 Primary 370 (45)
 ≥Secondary 377 (45)
HIV status, n (%)
 Positive 115 (14)
 Unknown 94 (11)
Number of visits, median (IQR) 21 (17–24)
IPTp-SP, n (%)
 One dose 120 (15)
 ≥2 doses 563 (68)
Gestational age at inclusion (weeks), n (%)
 <15 145 (15)
 [15 to <20−) 444 (45)
 [20 to <24−) 224 (23)
 ≥24 173 (17)
Malaria exposure
 Placental malaria, n (%) 15 (3)
 No malaria 626 (76)
 1 episode 161 (19)
 >1 episode 37 (4)
Malaria infections by gestation age (weeks), n (number at risk)
 <15 12 (120)
 [15–20) 109 (630)
 [20–24) 80 (822)
 ≥24 218 (986)
% of time ITN is used, median (IQR) 88 (56–96)
Infant characteristics
Preterm delivery, n (%) 48 (6)
Gestational age at birth, media (IQR) 40 (39–41)
Small for gestational age, n (%) 140 (21)
Caesarean section, n (%)
 n (%) 124 (16)
 % with HIV infection 21
Female, n (%) 452 (54)
Breastfeeding
 Number started, n (%) 808 (97)
 Median duration, months (IQR) 4.6 (6.0–7.7)
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Table 2 Factors other than malaria exposure during pregnancy associated with infant growth or morbidity
a Relative risk with 95 % confidence interval
b Per 10 years (centered)
c ≥Secondary level or primary level versus no education
d Compared to mother living in town
e Primipare versus multipare
f C section versus vaginal delivery
g Weeks
h Weeks
i Rainy versus dry season
Variable Weight growth Height growth Malariaa Diarrhoeaa Acute respiratory 
infectiona
Mother ageb 0.01 (−0.01 to 0.03) 0.00 (−0.08 to 0.07) 0.97 (0.89–1.07) 0.98 (0.94–1.03) 0.98 (0.95–1.01)
Mother education levelc
 Primary 0.01 (−0.25 to 0.28) 1.50 (0.51 to 2.49) 2.34 (0.53–10.39) 1.10 (0.63–1.93) 1.77 (1.16–2.77)
 ≥Secondary 0.21 (−0.07 to 0.49) 2.01 (0.97 to 3.04) 1.97 (0.41–9.54) 0.83 (0.45–1.52) 1.53 (0.98–2.39)
Residence aread −0.05 (−0.20 to 0.11) 0.27 (−0.34 to 0.88) 1.31 (0.59–2.90) 0.79 (0.55–1.14) 1.21 (0.95–1.54)
Mother HIV status −0.22 (−0.45 to 0.02) −0.60 (−1.49 to 0.30) 2.06 (0.54–7.82) 1.62 (1.00–2.62) 0.86 (0.60–1.24)
Paritye 0.14 (−0.05 to 0.32) 0.18 (−0.54 to 0.90) 0.83 (0.34–2.14) 0.96 (0.63–1.69) 0.76 (0.57–1.00)
Mode of deliveryf 0.33 (0.11 to 0.55) −0.13 (−1.00 to 0.74) 1.63 (0.53–5.05) 1.04 (0.58–1.85) 1.02 (0.71–1.36)
Average time with net during 
pregnancyg
0.09 (−0.13 to 0.31) 0.25 (−0.66 to 1.16) 0.87 (0.30–2.47) 0.83 (0.52–1.34) 0.98 (0.71–1.36)
Duration of breastfeedingh −0.18 (−0.52 to 0.16) −0.68 (−1.96 to 0.60) 1.00 (0.95–1.05) 1.01 (0.98–1.03) 0.99 (0.97–1.00)
Child sex −0.53 (−0.68 to −0.38) −1.47 (−2.06 to −0.88) 3.69 (1.47–9.29) 1.10 (0.77–1.56) 0.82 (0.65–1.03)
Pre-term delivery −0.05 (−0.35 to 0.26) 1.75 (0.52 to 2.97) 0.96 (0.22–4.17) 0.75 (0.33–1.72) 0.72 (0.43–1.21)
Small for gestational age −0.16 (−0.35 to 0.03) −0.07 (−0.81 to 0.66) 0.53 (0.15–1.78) 1.85 (1.25–2.74) 1.10 (0.82–1.47)
Seasoni – – 0.78 (0.37–1.69) 1.16 (0.80–1.68) 0.95 (0.75–1.20)
Fig. 2 Weight and height growth with centiles for infants according to their exposure to malaria infection during pregnancy (MiP) (not exposed, 
exposed to MiP and exposed to >1 MiP) and to the occurrence of any malaria infection during their first year of life (childhood malaria)
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Infant malaria
During their first year of life, 45 (5  %) children experi-
enced at least one malaria episode, 416 (51 %) at least one 
acute respiratory infection and 177 (22  %) at least one 
diarrhoea episode. Of the 45 children with malaria only 
7 had more than one infection but analysis of malaria 
was restricted to first occurrence. There was a significant 
positive association between the risks of diarrhoea and 
acute respiratory infection (p  <  0.001) and a borderline 
association between the risks of malaria and of diarrhoea 
or acute respiratory infection (respectively p = 0.08 and 
p = 0.09). Only infections with Plasmodium falciparum 
were observed. The risk of malaria increased linearly over 
the first year of life (test for non linear trend: p =  0.8) 
and was higher in girls compared to boys (Table 2). The 
risk was similar between infants born to mother treated 
with quinine and those born to mother treated with AL 
(p  =  0.2). A higher risk of malaria infection in infants 
was consistently found across the different variables used 
for malaria exposure; the risk was increased threefold in 
infants born to mother who had peripheral malaria (RR 
2.97, 95 % CI 1.37–6.42) and more than tenfold in those 
born to a mother with placental malaria (10.42, 95  % 
CI 2.64–41.10). The risk of malaria was maximal when 
pregnancy malaria infection was confirmed (and treated) 
4–12  weeks before delivery (Fig.  3, top right panel). Of 
note, in an analysis restricted to the subset of infants 
born to mothers who had MiP, those born to mothers 
with placental malaria were at increased risk of malaria 
during infancy (RR 8.04, 95 % CI 1.53–42.22) with wide 
confidence intervals due to the small numbers of placenta 
positive cases. There was no significant interaction on the 
log scale between peripheral malaria during pregnancy 
and maternal gravidity (p  =  0.6). The small number of 
placental infections precluded meaningful interaction 
analysis.
Infant morbidity
Regarding acute respiratory infection, there was a greater 
risk of infection in children of mothers who experienced 
peripheral malaria (RR 1.32, 95  % CI 1.02–1.71) or pla-
cental malaria (RR 1.92, 95 % CI 0.96–3.84, p = 0.06). No 
interaction was detected either with maternal gravidity 
(p = 0.2) or malaria timing (Fig. 3).
Lastly, the risk of diarrhoea was mainly increased in 
children born SGA (Table 2). An increased risk of infec-
tion was observed in children of mothers who experi-
enced >1 malaria infection during pregnancy (RR 1.93, 
Fig. 3 Association between the timing of malaria during pregnancy (counted backward from delivery) and clinical outcomes in infant
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95  % CI 1.02–3.66 for >1 MiP compared to no infec-
tion) or placental malaria (RR 2.25, 95  % CI 0.79–6.45, 
p  =  0.12). The risk of diarrhoea was mainly increased 
when MiP occurred in the 4 weeks before delivery (3.48, 
95 % CI 1.50–8.03).
Discussion
In this study, microscopic malaria during pregnancy, 
more than one peripheral malaria infection or placental 
malaria infection, were associated with various impaired 
infant health outcomes during the first year of life, with 
greater adverse consequences when MiP was confirmed 
late in pregnancy.
A major association of malaria infection during preg-
nancy observed in this study was an increased risk of 
malaria during infancy, confirming previous reports [8–
12, 14]. While most studies have used placental infection 
as a surrogate for malaria exposure during pregnancy, 
this study found that the association was consistently 
observed using other surrogates for malaria exposure 
during pregnancy. It should however be noted that 
infants born to a mother with placental malaria were at 
far more risk even compared to infants born to a mother 
who had peripheral malaria during their pregnancy but 
no placental infection. An increased risk of infant malaria 
was also observed when maternal malaria occurred 
within the last 12 weeks before delivery. This result con-
forms with previous evidence showing increased infant 
mortality and malaria morbidity associated with mater-
nal malaria at the end of pregnancy [3, 13, 14]. The unex-
pected increased risk of malaria observed in girls may 
be due differences in the malaria prevention provided to 
girls and boys and calls for further investigations. A clear 
limitation of this analysis is the lack of measures of the 
actual individual exposure to malaria (i.e. local malaria 
transmission) although it has been shown that the asso-
ciation between placental malaria and infant malaria per-
sist even after adjusting for environmental exposure to 
malaria [10]. As a consequence, it is not possible to rule 
out that the associations between malaria during preg-
nancy and infant outcomes observed in this study could 
be due to a common exposure of mothers and offspring 
to higher malaria transmission. This limitation does not 
detract from the underlying message of the importance 
of preventing maternal malaria and of explaining to these 
mothers that their child has a high risk of malaria so they 
can avoid delays in seeking treatment when the child is 
unwell.
Detailed studies have related the number and timing of 
malaria infection in pregnancy to the impact on low birth 
weight [24, 37, 38]. In this analysis, infants born to moth-
ers who were exposed to ≥1 infection of MiP or placen-
tal malaria were at higher risk of impaired growth during 
the first year of life, which is consistent with results from 
two previous studies showing that MiP affects growth 
beyond the in utero period [6, 7]. In addition, in contrast 
to multiple or late malaria infections during pregnancy, 
a single infection occurring early in pregnancy and well 
treated with an efficacious regimen was not significantly 
associated with impaired growth during infancy. This 
highlights the importance of offering highly efficacious 
anti-malarials early in pregnancy to reduce the harmful 
effects of MiP. Mothers who had signs of placental infec-
tion were enrolled late in this cohort, possibly preventing 
the chance to detect a treatable peripheral malaria infec-
tion earlier in pregnancy or by chance really had malaria 
infection late in their pregnancy. This reinforces the ben-
efit of systematic anti-malarial treatment of mothers who 
did not receive antenatal IPTp during their pregnancy. 
In this context the utility of RDT to detect peripheral 
parasitaemia, probably of low density, in the presence of 
placental malaria is questionable. Quantitative PCR tech-
niques in these cases would allow a more comprehensive 
understanding of this dilemma reported frequently in the 
literature from African studies but such techniques are 
not readily available for the women who need them [39]. 
It should however be noted that this study does not allow 
a proper evaluation of the beneficial effect of frequent 
screening by RDT or of IPTp.
The consequence of MiP for the newborns in this 
study extended beyond the in utero period confirming 
results from Benin [15], the only other study that has 
examined this. In Mbarara, malaria infections were sys-
tematically screened with RDT at each visit and biologi-
cally confirmed with a BS. As a result it is unlikely that 
respiratory or diarrhoea symptoms were non-specific 
signs of undiagnosed malaria. In addition the associa-
tion between MiP and respiratory infections or diarrhoea 
in the first year of life were independent of the mothers’ 
HIV status and other characteristics. The rates of respira-
tory infection and diarrhoea observed in this study were 
low compared to those observed in other settings likely 
because of the intensive follow-up during pregnancy 
reducing rates of placental malaria and because of the 
active care provided to the infants [40, 41]. Nevertheless 
the increased morbidity observed has important public 
health consequences such as an increased risk of death, 
hospitalization and drug prescriptions. The exact mecha-
nism of the materno-fetal immune response leading to 
this increased infectious morbidity is important although 
there are few studies with accurate data on timing of MiP 
and longitudinally followed mothers and infants to con-
tribute. An excellent summary of available studies pro-
viding evidence for the pathophysiological relationship 
between malaria in infancy in relation to MiP hypoth-
esizes reduced antibody transfer in placental MiP and 
Page 8 of 9De Beaudrap et al. Malar J  (2016) 15:92 
differences in the immune tolerance effects possibly due 
to HLA-G polymorphisms as underlying mechanisms but 
also acknowledges this information is incomplete [42]. 
Inference suggests that these changes in immunity due to 
MiP may be generalized and affect or interact with infant 
immune responses to non-malaria infection although 
evidence for this is currently sparse [15]. While an 
important strength of this study was the accurate deter-
mination of GA using gold standard ultrasound dating, 
several limitations should also be acknowledged. First, 
ultrasound dating was not available for all mothers. As a 
result some infant–mother pairs had to be excluded from 
this analysis, which might have resulted in some bias and 
lack of power. As the initial basis for the cohort was the 
assessment of malaria treatment for women in the 2nd 
and 3rd trimester, only a limited number of women were 
enrolled very early in pregnancy. Therefore, the effect of 
early malaria infection during pregnancy could not be 
assessed accurately from this data. Although accounting 
for left censoring with multiple imputation is expected 
to reduce bias, it should be emphasized that this method 
works under the assumption that missing data are non-
informative which may not be true. Moreover, some con-
founders were not accurately measured and surrogate 
markers had to be used. For instance, only maternal HIV 
status or the time spent under a net were available. Nev-
ertheless, the observed associations between MiP and 
infant morbidities suggests that these results are robust 
despite some possible residual confounding, and are 
important from a public health perspective.
Conclusion
This study shows that, despite active screening and treat-
ment, and IPTp for the majority of women, MiP, par-
ticularly late pregnancy infection, was associated with 
impaired infant growth and with both malaria and non-
malaria infections during the first year of life. Preven-
tion of MiP in pregnancy by efficacious treatment has the 
potential to reduce the significant burden of adverse con-
sequences for mothers and infants.
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Appendix: Multiple imputation correction 
for incompletely observed malaria exposure [43]
At each time period Ti, let X be the true MiP status indi-
cator: X =  1 if a malaria infection was detected during 
Ti and X = 0 if no malaria infection was detected AND 
the observation was complete. R indicates if the observa-
tion was complete (R = 1) or not (R = 0) and W is the 
observed but possibly mismeasured MiP status. X was 
considered as missing whenever W = 0 and R = 0. Miss-
ing X were imputed using standard multivariate impu-
tations by chained equations algorithm with W and the 
other covariates available. The number of imputations 
was increased to 50. For each imputed set, a regression 
model was fit and results were combined using Rubin’s 
formula [31].
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